The effect of Olibanum (Boswellia serrata) gel on clinical symptoms in patients with Osteoarthritis of the knee

The effect of Olibanum (Boswellia serrata) gel on clinical symptoms in patients with Osteoarthritis of the knee - a double-blind, placebo-controlled, randomized trials

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201210049670N1

Enrollment

Registered

2020-12-20

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Olibanum (Boswellia serrata) gel gel

Prepared on the basis of 2%Olibanum. To prepare 100 g of gel, 2 g of frankincense is extracted using propylene glycol solvent: water in a ratio of 80 to 20 is extracted by massaging method. The gel is

Also, using carbomer 940, distilled water and titanium dioxide are prepared as dyes.

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients more than 40 and less than 70 Patients with a diagnosis of osteoarthritis grade 1,2,3 knee pain Morning knee dryness less than 30 minutes Crepitus Osteophyte in radiography

Exclusion criteria

Exclusion criteria: History of rheumatoid arthritis, gout, CPPD Existence of uncontrolled cardiovascular disease Proven malignancy Severe kidney disease (creatinine above 3 Mg /Dl) Receive oral corticosteroids 4 weeks in advance Take NSAIDs with a dose of more than 50 mg daily except aspirin and acetaminophen up to a dose of more than 650 mg daily Intra-articular administration of the drug in the previous three months The patient's unwillingness or ability to fill in the text of the questionnaire used in the study The patient's unwillingness to continue participating in the study

Design outcomes

Primary

Measure	Time frame
BMI. Timepoint: The beginning of the study. Method of measurement: Weighing with scales and height with meters.;KOOS questionnaire PAIN. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;KOOS questionnaire Light daily activity. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;KOOS questionnaire Intense and sports activity. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;Quality of Life. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;Acetaminophen intake per day. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on biography.	—

Measure

Time frame

BMI. Timepoint: The beginning of the study. Method of measurement: Weighing with scales and height with meters.;KOOS questionnaire PAIN. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;KOOS questionnaire Light daily activity. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;KOOS questionnaire Intense and sports activity. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;Quality of Life. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on a questionnaire filled out by the patient himself.;Acetaminophen intake per day. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Based on biography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoshanak Mokaberinejad

Shahid Beheshti University of Medical Sciences

mokaberi@sbmu.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026